The present invention pertains to novel 7,9-substituted tetracycline
compounds. These tetracycline compounds can be used to treat numerous
tetracycline compound-responsive states, such as bacterial infections and
neoplasms, as well as other known applications for minocycline and
tetracycline compounds in general, such as blocking tetracycline efflux
and modulation of gene expression.